Semaglutide
Approved pharmaceutical GLP-1 therapy
Brief Overview: Semaglutide is a GLP-1 receptor agonist with approved uses in diabetes, obesity/weight management, and cardiovascular-risk contexts depending on product and label. It is not a research peptide in the same sense as BPC-157 or MOTS-c. Evidence lens: The evidence base is strong, but the formulation matters. Ozempic, Wegovy injection, Wegovy tablets, and Rybelsus have different labels, doses, administration rules, and outcome data. Compounded or counterfeit products are a separate risk category. How to read this: if you're new, understand that slow titration is not optional convenience; It reduces GI side effects while the long half-life accumulates. Once you're past the basics, track body composition, A1c, blood pressure, renal function during dehydration, gallbladder symptoms, pancreatitis symptoms, and weight-maintenance planning.
- Semaglutide is a synthetic analog of the naturally occurring human Glucagon-Like Peptide-1 (GLP-1) hormone.
- Originally developed by Novo Nordisk, it has 94% structural homology to human GLP-1.
- Modifications include a “spacer” and a fatty acid chain that allow it to bind to albumin, drastically extending its half-life to approximately 7 days.
- It is classified as a long-acting GLP-1 receptor agonist (GLP-1 RA).
- Semaglutide is an approved GLP-1 receptor agonist with distinct injection and oral tablet formulations. Oral semaglutide success is formulation-specific and does not prove that arbitrary oral peptides work.
The Multi-System Metabolic Master Semaglutide operates by activating GLP-1 receptors in three primary areas:
- The Brain (Hypothalamus): It signals the brain to increase feelings of satiety (fullness) and significantly reduce food cravings (“food noise”).
- The Stomach: It slows gastric emptying, keeping food in the stomach longer and extending the sensation of fullness after meals.
- The Pancreas/Liver: It stimulates glucose-dependent insulin secretion (only when blood sugar is high) and suppresses glucagon release, which prevents the liver from dumping excess sugar into the blood.
- It activates GLP-1 receptors to reduce appetite, slow gastric emptying, improve glucose-dependent insulin secretion, and reduce glucagon. Effects are dose-, indication-, and formulation-specific. The mechanism here is a plausibility map, not proof of a clinical outcome.
The “Oral Breakthrough”: On December 22, 2025, the FDA approved the first oral Wegovy pill (semaglutide 25 mg daily) for weight loss, achieving 16.6% mean weight loss with full adherence (13.6% in intention-to-treat analysis). Full US launch began January 2026.
- Wegovy HD (March 2026): FDA approved Wegovy HD (semaglutide 7.2 mg injection) on March 19, 2026, delivering 20.7% mean weight loss, the highest for any semaglutide injection. Available April 2026.
- Orforglipron / Foundayo (April 2026): Eli Lilly received FDA approval for Foundayo (orforglipron), a once-daily oral small-molecule GLP-1, on April 1, 2026. First oral GLP-1 that can be taken any time of day without food or water restrictions. ~12.4% weight loss at highest dose. Cardiovascular &
- Kidney Benefits: 2025 research expanded its use to reducing major adverse cardiovascular events (MACE) and chronic kidney disease (CKD) progression in adults with Type 2 Diabetes.
- MASH Treatment: Clinical trials in late 2025 have validated semaglutide’s efficacy in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), reducing liver fibrosis in non-cirrhotic patients.
- Weight Regain Data: A 2026 meta-analysis confirms “rapid weight regain” upon cessation of GLP-1 therapy without a comprehensive maintenance plan, reinforcing the drug as a long-term management tool.
- Semaglutide has strong clinical trial and label evidence for diabetes/weight/CV contexts depending on product. This is different from most research peptides in the guide. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: WEGOVY injectable semaglutide FDA-label escalation [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: WEGOVY injection: 0.25 mg weekly weeks 1-4; 0.5 mg weeks 5-8; 1 mg weeks 9-12; 1.7 mg weeks 13-16; Maintenance week 17 onward per indication.; Frequency: Once weekly; Timing: Same day each week; Abdomen, thigh, or upper arm; Any time of day with or without meals; Duration: Escalation over at least 16 weeks; Chronic maintenance if clinically appropriate; Max: Weight reduction adults: 1.7 or 2.4 mg weekly (2.4 mg recommended); If 2.4 mg tolerated ≥4 weeks and additional reduction is indicated, may increase to 7.2 mg weekly per 2026 label.; Titration/loading: Delay escalation 4 weeks if not tolerated. Pediatric weight maintenance: 2.4 mg recommended or 1.7 mg. MASH: 2.4 mg weekly, decrease to 1.7 if not tolerated.; Status: Yes - FDA-approved label/product protocol for labeled indications only.
- Protocol 2: Oral semaglutide FDA-label protocols: WEGOVY tablets vs RYBELSUS/OZEMPIC tablets [FDA/Approved/Label]; Route: Oral tablet; Dose: WEGOVY tablets: 1.5 mg daily days 1-30 → 4 mg days 31-60 → 9 mg days 61-90 → 25 mg daily day 91 onward. RYBELSUS: 3 mg daily days 1-30 → 7 mg daily days 31-60 → maintain 7 mg or increase to 14 mg daily on day 61+ if needed.; Frequency: Once daily; Timing: Morning, empty stomach, with up to 4 oz water; Wait at least 30 minutes before food, beverage, or other oral medication.; Duration: Daily chronic therapy per labeled indication and response/tolerability; Max: WEGOVY tablets: 25 mg daily. RYBELSUS: 14 mg daily. Any 50 mg oral semaglutide row is research/non-FDA unless tied to a specific approved product label.; Titration/loading: Do not combine the WEGOVY tablet titration and RYBELSUS titration as though they are interchangeable; They are separate labeled products/regimens.; Status: Yes - FDA-approved label/product protocols for their respective labeled indications only.
- Protocol 3: WEGOVY FDA-label escalation to maintenance [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: WEGOVY injection initiation 0.25 mg weekly; Titrate 0.5, 1, 1.7 mg at 4-week intervals toward indication-specific maintenance.; Frequency: Once weekly; Duration: Escalate every 4 weeks per label to maintenance; Max: 2.4 mg weekly recommended maintenance for most weight/CV/MASH contexts; Adult weight-reduction label allows increase to 7.2 mg weekly if 2.4 mg tolerated ≥4 weeks and additional weight reduction is clinically indicated.; Titration/loading: Weeks 1-4: 0.25 mg; Weeks 5-8: 0.5 mg; Weeks 9-12: 1 mg; Weeks 13-16: 1.7 mg; Week 17 onward: 1.7/2.4 mg or 7.2 mg in eligible adult weight-reduction context.; Status: Yes - FDA-approved label/product protocol for labeled indication only.
- Protocol 4: WEGOVY HD 7.2 mg FDA-label adult weight-reduction escalation ceiling [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: 7.2 mg once weekly only after WEGOVY 2.4 mg once weekly has been tolerated for at least 4 weeks and additional weight reduction is clinically indicated.; Frequency: Once weekly; Timing: Same day each week; Abdomen, thigh, or upper arm; Duration: Adult weight-reduction maintenance/escalation context after standard WEGOVY titration; Max: 7.2 mg SC once weekly for eligible adult weight-reduction context under 2026 WEGOVY label; Titration/loading: Standard WEGOVY titration to 2.4 mg first; Tolerate 2.4 mg ≥4 weeks before 7.2 mg escalation.; Status: Yes - FDA-approved label/product protocol for labeled adult weight-reduction context only.
- Label titration and product form control dosing. Compounded or salt-form products are not equivalent to approved branded products without clear legal and quality context. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Half-life basis: Approximately 1 week. This is label-supported for semaglutide products; It also explains why missed-dose and washout windows are long.
- Estimated time until steady state: 4-5 weeks on once-weekly dosing.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- Practical interpretation: Semaglutide has an exceptionally long half-life (~165 hours, ~1 week) due to its albumin-binding fatty-acid side chain, enabling once-weekly subcutaneous dosing. The oral form (Rybelsus, Wegovy Pill) uses the SNAC absorption enhancer to overcome low intrinsic GI bioavailability and is dosed daily on an empty stomach. Steady-state plasma concentrations are reached after 4 to 5 weeks of consistent dosing. Feature Semaglutide (Wegovy) Tirzepatide (Zepbound) Retatrutide (Triple) Targets GLP-1 only GLP-1 + GIP GLP-1 + GIP + Glucagon Avg Weight Loss ~15% ~21% ~24% (Phase 2 data) Formulation Injection & Pill Injection Only Injection Only Side Effects Standard GI Lower GI (relative) Higher heart rate risk
- Weekly SC semaglutide and daily oral semaglutide have different exposure logic. Oral tablets rely on SNAC/formulation and strict administration conditions. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
L-Carnitine: Often co-administered (especially in compounded versions) to assist with fatty acid transport during rapid weight loss.
- BPC-157: Researched as a potential stack to mitigate the “nausea” and GI inflammation side effects common with GLP-1s.
- Metformin: Frequently used alongside semaglutide to provide synergistic blood sugar control and weight loss.
- Stacking with tirzepatide, retatrutide, cagrilintide, or other appetite agents increases overlapping GI and nutrition risks. Combination therapy should be product- and clinician-directed. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Gastrointestinal (Most Common): Nausea (44%), diarrhea (30%), and vomiting. These are usually transient and occur during dose escalation. “Semaglutide Face/Body”: Rapid weight loss can lead to loss of facial volume and muscle mass; Protein-heavy diets and resistance training are recommended.
- Serious Risks: Pancreatitis, gallbladder disease, and acute kidney injury (often due to dehydration from vomiting/diarrhea).
- Boxed Warning: Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Monitor GI intolerance, pancreatitis/gallbladder symptoms, dehydration/renal injury, hypoglycemia with insulin/secretagogues, thyroid C-cell warning context, and malnutrition from overly rapid weight loss. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- HgbA1c & Fasting Glucose: Primary markers for metabolic improvement.
- Amylase/Lipase: To monitor for asymptomatic pancreatic stress.
- Cystatin C: Preferred over Creatinine in 2026 for monitoring kidney function during rapid weight loss.
- Gallbladder Ultrasound: Indicated if the patient experiences severe right-side abdominal pain.
- Track weight-loss rate, glucose/A1c, renal function if severe GI symptoms occur, gallbladder symptoms, nutrition/protein, lean mass, and oral medication absorption concerns. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Approved (Ozempic, Wegovy, Rybelsus). Wegovy approved for MACE risk reduction in obesity (2024). Expanded cardiovascular-risk-reduction label pending (expected 2026).
- EU (EMA): Approved. Added stroke-risk-reduction label September 2025 based on SOUL trial.
- Compounding Status: Novo Nordisk is actively opposing compounded semaglutide; The legal status of compounding remains contested in 2026.
- April 2026 (503B Bulks List): FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances now that FDA-approved versions are widely available. Commissioner Marty Makary framed the action as protecting patients and preserving drug-approval integrity. If finalized, 503B outsourcing facilities cannot compound these drugs from bulk powder, narrowing compounding lanes left after the 2024-2025 shortage-list removals. 503A pharmacies operate under a separate framework and are not directly addressed by this action.
- WADA: Not on prohibited list.
- Availability: Prescription pharmaceutical; Widely available through standard pharmacies.
- Semaglutide has FDA-approved products, while bulk-compounded and research-market semaglutide raise separate legal and quality issues. FDA has proposed excluding semaglutide from the 503B bulks list. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.
6. [G] FDA. (2025). Wegovy (semaglutide) prescribing information. FDA AccessData.
7. [G] FDA. (2025). Ozempic (semaglutide) prescribing information. FDA AccessData.
8. [RouteEvidence] DailyMed WEGOVY semaglutide injection and tablet label.
9. [RouteEvidence] DailyMed RYBELSUS / OZEMPIC oral semaglutide tablet label.